Wikipedia -WSS

Wikipedia

author：knowledge 2025-08-12 08:27:40 - browse：53

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： A new study sees potential in DNA sequencing of infants

hotspot

WSS

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Juul spent big to court Black leaders to promote its e

Juul spent big to court Black leaders to promote its e

How the political right came to back psychedelics to treat trauma

New Ultima Genomics DNA sequencer can read genome for $100

New research casts further doubt on a common procedure used with IVF

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Oak trusses raised to roof of fire

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bulgari apologizes to China for listing Taiwan as a country after online backlash

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Do digital therapeutics have a future in medicine?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

DIEP, the 'gold standard' of breast reconstruction, is under threat

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

entertainment

Woodcock on FDA’s accelerated approval and her next chapter

Apple Vision Pro: A first look at health apps on the new VR headset

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Palantir health business leans on meeting customers’ needs

General Catalyst, Summa Health deal will turn on physician buy

Retired US general questions alleged Putin, Prigozhin meeting

explore

explore

hotspot

hotspot